Zhitong Finance APP News, Haite Bio (300683.SZ) released the 2020 annual report, the company's operating income for the year was 524 million yuan, a year-on-year decrease of 15.49%. The net loss attributable to shareholders of the listed company was 25.0257 million yuan, a year-on-year turnaround. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 42.1969 million yuan, a year-on-year turnaround. Basic loss per share was 0.24 yuan. The specific reason for the substantial loss of
's performance is: the sales of mouse nerve growth factor for injection, the company's existing product, has declined. In August 2019, the 2019 version of the National Medical Insurance Catalogue was released. It will be officially implemented from January 1, 2020. The mouse nerve growth factor for injection will be transferred out of the medical insurance, and the relevant regulations in the medical insurance policy will not change significantly in the short term. Sales of the company's existing product, mouse nerve growth factor for injection, were further adversely affected. During the reporting period, the company continued to increase research and development efforts, and the research and development expenses increased. The research and development expenses increased by 23.47 million yuan compared with 2019. The proportion of research and development expenses to revenue increased from 10.10% in 2019 to 16.43%, mainly due to outsourced research and development projects and Depreciation expense increases. In the 2020 annual report, the company conducted an impairment test on goodwill, and conducted a goodwill impairment of Zhuhai Haitai by 12.15 million yuan.
